NCM and ImaginAb to commercialize Zr-89

Kathy Mahdoubi | | Health Imaging | Molecular Imaging

New York City-based PET radiopharmaceutical development company NCM USA announced this month that ImaginAb will be working on labeling zirconium-89 (Zr-89) and manufacturing practice in a new long-term contract with NCM.

NCM specializes in cyclotron-derived PET radiopharmaceuticals with manufacturing facilities located in the Bronx.

"Our ultra-modern facility in New York has allowed us to attract highly innovative companies such as ImaginAb to develop advanced biologics-based products for PET imaging and we are pleased that ImaginAb selected us as a partner," said NCM president Anwer Rizvi in a press release. "Our mission is to elevate the status of centralized PET drug manufacturing to the standard that the biopharma industry has enjoyed for many years."

ImaginAb’s expertise is radiopharmaceuticals that incorporate the company’s proprietary antibody fragment platform. Multiple partnerships are being secured to develop companion diagnostics in oncologic and immuno imaging.

"NCM is an example of what a technology-enabled PET manufacturing facility can be and where the field ultimately needs to progress in terms of flexibility and multi-isotope production,” said Christian Behrenbruch, CEO of ImaginAb. “We have chosen to partner with NCM to bring rapid clinical proof-of-concept development capabilities to both internal pipeline development and potentially some of our third-party pharma collaborations."

Kathy Mahdoubi

Related Content

Researchers receive grant worth millions to develop portable PET scanner
Why is the US still dependent on foreign medical isotope production?
Downed high-flux reactor could restart sooner than anticipated
Some nuc med departments are already feeling the strain of the isotope shortage
NorthStar opens facility to assist with development and distribution of vital radioisotopes
Lizard saliva could be key to spotting elusive pancreatic tumors

Around the web

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.